Azitra, Inc. (AZTR)
| Market Cap | 3.72M -18.7% |
| Revenue (ttm) | n/a |
| Net Income | -11.81M |
| EPS | -1.43 |
| Shares Out | 16.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,370,543 |
| Open | 0.2130 |
| Previous Close | 0.2053 |
| Day's Range | 0.2059 - 0.2350 |
| 52-Week Range | 0.1000 - 2.3980 |
| Beta | -1.39 |
| Analysts | Buy |
| Price Target | 0.78 (+239.13%) |
| Earnings Date | May 13, 2026 |
About AZTR
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Ph... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for AZTR stock is "Buy" and the 12-month stock price target is $0.78.
News
Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
BRANFORD, Conn., May 27, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...
Azitra Proxy statement: Proxy filing
Azitra filed a proxy statement on May 27, 2026, providing details for shareholder voting and corporate governance matters.
Azitra files to sell 255.7M shares of common stock for holders
16:58 EDT Azitra (AZTR) files to sell 255.7M shares of common stock for holders
Azitra Registration statement: Registration filing
Azitra filed a registration statement on May 21, 2026, providing details about a securities offering with the SEC.
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
BRANFORD, Conn., May 13, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...
Azitra Quarterly report: Q1 2026
Azitra has published its Q1 2026 quarterly earnings report on May 13, 2026.
Azitra Earnings release: Q1 2026
Azitra released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Azitra Proxy statement: Proxy filing
Azitra filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
Azitra granted new U.S. patent protecting ATR-12 program
Azitra (AZTR) announced the issuance of a new U.S. patent protecting ATR-12, the company’s lead product candidate. Azitra is advancing ATR-12 in a Phase 1b clinical trial as a treatment…
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
Patent offers broad protections for ATR-12, an engineered strain of S. epidermidis that expresses a fragment of human LEKTI protein ATR-12 is currently the subject of a Phase 1b trial for the treatmen...
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
Preclinical data demonstrate ATR-01 delivers functional filaggrin, restoring skin barrier integrity and supporting advancement toward first-in-human studies BRANFORD, Conn., April 28, 2026 /PRNewswire...
Azitra Proxy statement: Proxy filing
Azitra filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Why Is Azitra Inc Stock (AZTR) Up Today?
Azitra Inc stock climbed on Friday after the company revealed details of a private placement.
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
Initial funding of approximately $10.5MM in convertible preferred stock and up to an additional $20.9MM upon cash exercise of warrants Financing marks launch of Azitra new innovative protein and pepti...
Azitra Inc trading halted, news pending
12:23 EDT Azitra (AZTR) Inc trading halted, news pending
Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
BRANFORD, Conn., March 5, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for...
Azitra Proxy statement: Proxy filing
Azitra filed a proxy statement on March 5, 2026, providing details for shareholder voting and corporate governance matters.
Azitra Slides: Corporate presentation
Azitra has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermat...
Azitra Annual report: Q4 2025
Azitra has published its Q4 2025 annual report on February 27, 2026.
Azitra Earnings release: Q4 2025
Azitra released its Q4 2025 earnings on February 27, 2026, summarizing the period's financial results.
Azitra adds MD Anderson Cancer Center as site for Phase 1/2 skin rash trial
Azitra (AZTR) added The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04. ATR-04 is a first-in-class, topically applied…
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestones BRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- Azit...